Report Details Misleading Ads for Unapproved Online Drugs
A new analysis finds online vendors often use misleading claims and omit key safety data when advertising non-FDA-approved compounded drugs, drawing increased FDA enforcement.
A study by DLA Piper highlights widespread misleading advertising and safety omissions by online pharmacies and telehealth platforms promoting non-FDA-approved compounded drugs. The analysis of 23 vendors found that 52% made unsupported efficacy claims and 43% had incomplete or misleading safety warnings, particularly for popular treatments in weight loss, erectile dysfunction, and hair loss.
This trend poses a significant risk for the pharmaceutical and telehealth industries, as consumers are often unable to distinguish between FDA-approved medicines and unvetted compounded formulations. The report notes that consumer trust is misplaced, with many believing online sellers are already approved by regulators. In response, the FDA has sharply increased enforcement, issuing over 100 warning letters since September 2025, primarily targeting providers of compounded GLP-1 drugs.
Counsel for life sciences and telehealth clients should advise an immediate review of all marketing and promotional materials for compounded products to ensure compliance with FDA standards and avoid enforcement actions, which are expected to intensify.